# Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

> **NCT03004495** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 36 (actual)

## Conditions studied

- Copd

## Interventions

- **DRUG:** CHF5259 and CHF6001
- **DRUG:** CHF5259 + placebo
- **DRUG:** CHF6001 + placebo
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03004495
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004495, "Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03004495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*